Bioxytran, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 4.28 million compared to USD 2.46 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0964 USD | +2.55% |
|
+4.78% | -35.73% |
04-19 | Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-19 | Bioxytran, Inc. Announces Board Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-35.73% | 17.08M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- BIXT Stock
- News Bioxytran, Inc.
- Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023